These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 22198210

  • 1. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.
    Melaiu O, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R, Foddis R, Gemignani F, Pellegrini S, Landi S.
    Mutat Res; 2012; 750(2):132-140. PubMed ID: 22198210
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
    Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba II.
    Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
    [Abstract] [Full Text] [Related]

  • 4. MicroRNAs dysregulation in human malignant pleural mesothelioma.
    Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, Martini F, Tognon MG.
    J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
    [Abstract] [Full Text] [Related]

  • 5. Expression status of candidate genes in mesothelioma tissues and cell lines.
    Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S.
    Mutat Res; 2015 Jan; 771():6-12. PubMed ID: 25771974
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.
    Dong L, Jensen RV, De Rienzo A, Gordon GJ, Xu Y, Sugarbaker DJ, Bueno R.
    BMC Med Genet; 2009 Dec 31; 10():149. PubMed ID: 20043850
    [Abstract] [Full Text] [Related]

  • 8. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
    Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G.
    Int J Oncol; 2010 Aug 31; 37(2):437-44. PubMed ID: 20596671
    [Abstract] [Full Text] [Related]

  • 9. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
    Tian K, Bakker E, Hussain M, Guazzelli A, Alhebshi H, Meysami P, Demonacos C, Schwartz JM, Mutti L, Krstic-Demonacos M.
    J Transl Med; 2018 Oct 13; 16(1):282. PubMed ID: 30316293
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
    Ramírez-Salazar EG, Salinas-Silva LC, Vázquez-Manríquez ME, Gayosso-Gómez LV, Negrete-Garcia MC, Ramírez-Rodriguez SL, Chávez R, Zenteno E, Santillán P, Kelly-García J, Ortiz-Quintero B.
    Exp Mol Pathol; 2014 Dec 13; 97(3):375-85. PubMed ID: 25236577
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
    Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ, Bueno R.
    J Pathol; 2007 Mar 13; 211(4):439-46. PubMed ID: 17253597
    [Abstract] [Full Text] [Related]

  • 15. Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.
    Milosevic V, Kopecka J, Salaroglio IC, Libener R, Napoli F, Izzo S, Orecchia S, Ananthanarayanan P, Bironzo P, Grosso F, Tabbò F, Comunanza V, Alexa-Stratulat T, Bussolino F, Righi L, Novello S, Scagliotti GV, Riganti C.
    Int J Cancer; 2020 Jan 01; 146(1):192-207. PubMed ID: 31107974
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
    Borchert S, Suckrau PM, Walter RFH, Wessolly M, Mairinger E, Steinborn J, Hegedus B, Hager T, Herold T, Eberhardt WEE, Wohlschlaeger J, Aigner C, Bankfalvi A, Schmid KW, Mairinger FD.
    Sci Rep; 2020 Oct 29; 10(1):18677. PubMed ID: 33122816
    [Abstract] [Full Text] [Related]

  • 18. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
    Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F, Szlosarek PW.
    Pharmacol Rep; 2023 Jun 29; 75(3):570-584. PubMed ID: 37010783
    [Abstract] [Full Text] [Related]

  • 19. Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
    Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Barletta G, Biello F, Maggioni C, Grossi F.
    Microrna; 2016 Jun 29; 5(1):12-18. PubMed ID: 26817512
    [Abstract] [Full Text] [Related]

  • 20. Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray.
    Mohr S, Keith G, Galateau-Salle F, Icard P, Rihn BH.
    Biochim Biophys Acta; 2004 Jan 20; 1688(1):43-60. PubMed ID: 14732480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.